Statistical Analysis Plan (SAP): A randomised, double-dummy, triple-blind, active placebo-controlled, parallel groups trial of LSD microdosing in patients with major depressive disorder (LSDDEP2)
Dimitri Daldegan-Bueno, Suresh Muthukumaraswamy, Alana Cavadino
Open MIND November 17, 2025 DOI: 10.17605/osf.io/tk739 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Statistical analysis plan Randomized Placebo-controlled Peer reviewed |
|---|---|
| Topics | Depression LSD Microdosing |
| Key points | The SAP specifies that analyses will assess the efficacy and safety of LSD (MB-22001) versus active placebo (caffeine), covering primary, secondary, and safety endpoints. No results are reported. |
Abstract
The analyses described in this SAP will assess the efficacy and safety of LSD (MB-22001) in comparison with active placebo (caffeine). The analysis described cover those for the primary, secondary and safety endpoints described in the Protocol.
In the evidence
This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.
-
Specifies analyses to assess efficacy and safety of LSD versus active placebo (caffeine) in a trial of patients with major depressive disorder; no results are reported.
Synthesized